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Background
Advanced melanoma is associated with a poor prognosis.
Targeted therapy and immunotherapy are mainstays of
treatment. High-dose interleukin-2 (HD IL-2), interferon
alfa-2b, cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) inhibitors, and programmed cell death protein
1 (PD-1) inhibitors are approved immunotherapies.
Genetically engineered T cells targeting melanoma anti-
gens are currently under investigation. Patients with
advanced melanoma are often exposed to multiple
immunotherapies over their disease course. Adverse
implications of sequential use of these therapies is not
well described. Here we present a case of a patient with
metastatic melanoma who developed rhabdomyolysis and
vitiligo after various courses of immunotherapy.
Methods
This is a 42 year old male with BRAF wild type melanoma
metastatic to axilla, lung, and small bowel. Initial treat-
ment consisted of four doses of ipilimumab with disease
progression. He then enrolled in a clinical trial using flu-
darabine and cyclophosphamide conditioning for geneti-
cally engineered autologous T cells targeting tyrosinase.
He experienced disease response lasting a few months but
then progressed. After three doses of pembrolizumab,
his disease again progressed, and he therefore initiated
HD IL-2. During the first course of HD IL-2 he developed
diffuse muscle pain due to rhabdomyolysis. HD IL-2 was
discontinued with resolution in symptoms and lab
abnormalities. Follow up imaging revealed a mixed
response and he was again challenged with HD IL-2.
He again rapidly developed rhabdomyolysis that resolved
with discontinuation of therapy and hydration. A muscle
biopsy was consistent with necrotizing myopathy with
macrophage and T cell infiltration. Repeat imaging two
months later revealed resolution of axillary lymphadeno-
pathy and lung nodules that decreased in size. He was
noted to have new onset diffuse vitiligo. A skin biopsy
revealed diffuse CD3+ T cell infiltrate.
Conclusions
The complications of sequential immunotherapy in
metastatic melanoma has not been well described. Our
patient experienced rhabdomyolysis after HD IL-2, which
followed ipilimumab, genetically engineered T cells and
pembrolizumab, respectively. It is unclear if previous
immunotherapy, especially genetically engineered T cells,
contributed to this unusual toxicity. Ultimately our
patient experienced a favorable clinical response as evi-
denced by the development of vitiligo and decrease in his
tumor burden. Vitiligo is an autoimmune process that
may have been enhanced by his previous exposure to var-
ious immunotherapies. Physicians should be alert for rare
and unexpected toxicities in patients who have received
multiple lines of immunotherapy.
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